How does Fragment 17-23 relate to full TB-500?

Fragment 17-23 contains the actin-binding LKKTETQ motif, considered the core functional region of thymosin beta-4 (TB-500). Researchers study it to isolate the repair-related activity of the larger molecule.

Is TB-500 Fragment 17-23 approved for human use?

No. It is an experimental research peptide studied in preclinical models. It has no regulatory approval and limited human safety data.

← All peptides

Healing & Recovery

Preclinical

TB-500 Fragment (17-23)

Also known as: TB-500 Fragment 17-23, Thymosin Beta-4 Fragment 17-23, TB4 Frag 17-23

TB-500 Fragment 17-23 is a short peptide corresponding to the actin-binding region of thymosin beta-4, studied for tissue repair and regeneration. It represents the core bioactive sequence often credited with TB-500's healing effects.

Mechanism of Action

Fragment 17-23 contains the LKKTETQ actin-binding motif of thymosin beta-4, which is central to the parent molecule's regulation of actin polymerization. By modulating the G-actin to F-actin equilibrium, the fragment is thought to promote cell migration, angiogenesis, and the recruitment of progenitor cells to sites of injury. It is also studied for downregulating inflammatory signaling and supporting extracellular matrix remodeling during wound healing.

Half-life: Short; small fragments are typically cleared within hours
Administration Routes: subcutaneous
Research Status: Preclinical